BRAF mutations in advanced cancers: Clinical characteristics and outcomes

PLoS ONE

Volumn 6, Issue 10, 2011, Pages

  El Osta, Hazem ^a   Falchook, Gerald ^a   Tsimberidou, Apostolia ^a   Hong, David ^a   Naing, Aung ^a   Kim, Kevin ^a   Wen, Sijin ^a   Janku, Filip ^a   Kurzrock, Razelle ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ADVANCED CANCER; AGED; BONE METASTASIS; BRAF GENE; BRAIN METASTASIS; CANCER LOCALIZATION; CANCER MORTALITY; CANCER SURVIVAL; CODON; COLORECTAL CANCER; CONTROLLED STUDY; ESOPHAGUS CANCER; FEMALE; GENE MUTATION; GENETIC ASSOCIATION; HUMAN; HUMAN TISSUE; LIVER METASTASIS; LUNG METASTASIS; MAJOR CLINICAL STUDY; MALE; MELANOMA; MUTATIONAL ANALYSIS; ONCOGENE; OUTCOME ASSESSMENT; OVARY CANCER; PROGRESSION FREE SURVIVAL; RETROPERITONEAL CANCER; REVIEW; SOFT TISSUE METASTASIS; SURVIVAL TIME; THYROID CANCER; TUMOR VOLUME; ADOLESCENT; ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; GENETICS; MIDDLE AGED; MUTATION; NEOPLASM; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; SURVIVAL;

B RAF KINASE; BRAF PROTEIN, HUMAN;

ADOLESCENT; ADULT; AGED; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MUTATION; NEOPLASMS; PROTO-ONCOGENE PROTEINS B-RAF; SURVIVAL ANALYSIS; TOMOGRAPHY, X-RAY COMPUTED; YOUNG ADULT;

EID: 80054790555     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0025806     Document Type: Review

References (36)

1. Flaherty KT, McArthur G, (2010) BRAF, a target in melanoma: implications for solid tumor drug development. Cancer 116 (21): 4902-4913.
2. Rubinstein JC, Sznol M, Pavlick AC, Ariyan S, Cheng E, et al. (2010) Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032. J Transl Med 8: 67.
3. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, et al. (2002) Mutations of the BRAF gene in human cancer. Nature 417 (6892): 949-954.
4. Infante JR, Fecher LA, Nallapareddy S, Gordon MS, Flaferty KT, et al. (2010) Safety and efficacy results from the first-in-human study of the oral MEK1/2 inhibitor GSK1120212. J Clin Oncol 28: 15s (suppl; abstr 2503).
5. Kefford R, Arkenau H, Brown MP, Millward M, Infante JR, et al. (2010) Phase I/II study of GSK2118436, a selective inhibitor of oncogenic mutant BRAF kinase, in patients with metastatic melanoma and other solid tumors. J Clin Oncol 28: 15s (suppl; abstr 8503).
6. Flaherty KT, Puzanov I, Kim K, Ribas A, McArthur GA, et al. (2010) Inhibition of mutated, activated BRAF in metastatic melanoma. N Eng J Med 363: 908-819.
7. Zuo Z, Chen SS, Chandra PK, Galbincea JM, Soape M, (2009) Application of COLD-PCR for improved detection of KRAS mutations in clinical samples. Mod Pathol 22: 1023-1031.
8. Eberhard D, Johnson B, Amler L, Goddard AD, Heldens SL, et al. (2005) Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 23: 5900-5909.
9. Curtin J, Busam K, Pinkel D, Bastian B, (2006) Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol 24: 4340-4346.
10. Nosho K, Kawasaki T, Ohnishi M, Suemoto Y, Kirkner GJ, et al. (2008) PIK3CA kinase in colorectal cancer: Relationship with genetic and epigenetic alterations. Neoplasia 10: 534-541.
11. Curtin J, Fridlyand J, Kageshita T, Patel HN, Busam KJ, et al. (2005) Distinct sets of genetic alterations in melanoma. N Eng J Med 353: 135-147.
12. Sakr R, Barbashina V, Morrogh M, Chandarlapaty S, Andrade VP, et al. (2010) Protocol for PTEN expression by immunohistochemistry in formalin-fixed paraffin-embedded human breast carcinoma. Appl Immunohistochem Mol Morphol 18: 371-374.
13. Arkenau HT, Barriuso J, Olmos D, Ang JE, de Bono J, et al. (2009) Prospective Validation of a Prognostic Score to Improve Patient Selection for Oncology Phase I Trials. J Clin Oncol 27: 2692-2696.
14. Greenman C, Stephens P, Smith R, Dalgliesh GL, Hunter C, et al. (2007) Patterns of somatic mutation in human cancer genomes. Nature 446: 153-158.
15. Shinozaki M, Fujimoto A, Morton DL, Hoon DS, (2004) Incidence of BRAF oncogene mutation and clinical relevance for primary cutaneous melanomas. Clin Cancer Res 10: 1753-1757.
16. Kumar R, Angelini S, Czene K, Sauroja I, Hahka-Kemppinen M, et al. (2003) BRAF mutations in metastatic melanoma: a possible association with clinical outcome. Clin Cancer Res 9: 3362-3368.
17. Long GV, Menzies AM, Nagrial A, Haydu L, Hamilton AL, et al. (2010) Clinico-pathologic correlates of BRAF mutation status in 207 consecutive patients with metastatic melanoma. J Clin Oncol 28: 15s (suppl; abstr 8548).
18. Chang D, Panageas K, Osman I, Polsky D, Busam K, et al. (2004) Clinical significance of BRAF mutations in metastatic melanoma. J Transl Med 2: 46.
19. Tran B, Kopetz S, Tie J, Gibbs P, Jiang Z, et al. (2010) Differences in sites of metastatic disease and outcomes observed in patients with BRAF mutant colorectal cancers. J Clin Oncol 28: 15s (suppl; abstr 3592).
20. Scoggins CR, Ross MI, Reintgen DS, Noyes RD, Goydos JS, et al. (2006) Gender-related differences in outcome for melanoma patients. Ann Surg 243: 693-8.
21. Balch CM, Soong SJ, Gershenwald JE, Thompson JF, Reintgen DS, et al. (2001) Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 19: 3622-3634.
22. Houben R, Becker JC, Kappel A, Terheyden P, Bröcker EB, et al. (2004) Constitutive activation of the Ras-Raf signaling pathway in metastatic melanoma is associated with poor prognosis. J Carcinog 3: 6.
23. Jovanovic B, Egyhazi S, Eskandarpour M, Ghiorzo P, Palmer JM, et al. (2010) Coexisting NRAS and BRAF mutations in primary familial melanomas with specific CDKN2A germline alterations. J Invest Dermatol 130: 618-620.
24. Sensi M, Nicolini G, Petti C, Bersani I, Lozupone F, et al. (2006) Mutually exclusive NRASQ61R and BRAFV600E mutations at the single-cell level in the same human melanoma. Oncogene 25: 3357-3364.
25. Joseph RW, Sullivan RJ, Panka D, Manoukian G, Percy A, et al. (2010) Effect of mutational status on response, PFS, or OS after treatment with IL-2 for metastatic melanoma. J Clin oncol 28: 15s (suppl; abstr 8597).
26. Sougklakos I, Saridaki Z, Tzardi M, Papadatos D, Patsos, et al. (2010) Use of BRAF mutations, microsatellite instability status, and cyclin D1 expression to predict metastatic colorectal patients' outcome. 2010 Gastrointestinal Cancers Symposium, Abst # 355.
27. Zlobec I, Bihl MP, Schwarb H, Terraciano L, Lugli A, (2010) Clinicopathological and protein characterization of BRAF- and K-RAS-mutated colorectal cancer and implications for prognosis. Int J Cancer 127: 367-380.
28. Richman SD, Seymour MT, Chambers P, Elliott F, Daly CL, et al. (2009) KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial. J Clin Oncol 27: 5931-5937.
29. Tie J, Gibbs P, Lipton L, Christie M, Jorissen RN, et al. (2011) Optimizing targeted therapeutic development: Analysis of a colorectal cancer patient population with the BRAFV600E mutation. Int J Cancer 128 (9): 2075-2084.
30. Loupakis F, Ruzzo A, Cremolini C, Vincenzi B, Salvatore L, et al. (2009) KRAS codon 61, 146 and BRAF mutations predict resistance to cetuximab plus irinotecan in KRAS codon 12 and 13 wild-type metastatic colorectal cancer. Br J Cancer 101: 715-721.
31. De Roock W, Claes B, Bernasconi D, De Schutter J, et al. (2010) Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 11: 753-762.
32. Linot B, Capitain O, Metges J, Adenis A, Raoul J, et al. (2010) Impact of PI3K, BRAF, and KRAS mutations on efficacy intensified FOLFIRI+cetuximab regimen in advanced colorectal cancer. 2010 Gastrointestinal Cancers Symposium, Abst # 365.
33. Tol J, Nagtegaal ID, Punt CJ, (2009) BRAF mutation in metastatic colorectal cancer. N Engl J Med 361: 98-99.
34. Xing M, Westra WH, Tufano RP, Cohen Y, Rosenbaum E, et al. (2005) BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab 90: 6373-6379.
35. Fugazzola L, Puxeddu E, Avenia N, Romei C, Cirello V, et al. (2006) Correlation between B-RAFV600E mutation and clinico-pathologic parameters in papillary thyroid carcinoma: data from a multicentric Italian study and review of the literature. Endocr Relat Cancer 13: 455-464.
36. Therasse P, Arbuck SG, Eisnehauer EA, Wanders J, Kaplan RS, et al. (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the Unites States, National Cancer Institute of Canada. J Natl Cancer Ins 92: 205-216.